Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K
Conditions
Keywords
ASP015K, healthy subjects, bioavailability, rheumatoid arthritis, psoriasis, transplantation
Brief summary
The purpose of this study is to determine the relative bioavailability and pharmacokinetic profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the safety and tolerability after a single dose of three different strengths of a new tablet formulation.
Detailed description
Eligible subjects will be admitted on Day-1 and remain confined on the unit for 16 days. Each subject will receive a single dose of study drug per the defined treatment periods on the mornings of Day 1, Day 6 and Day11. There will be a minimum of 5 days between each consecutive dose group. Any subject discontinuing the study prior to completion should have all end of study evaluations completed.
Interventions
DRUGASP015K
oral
Sponsors
Astellas Pharma Inc
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject weighs at least 45 kg and has a body mass index (BMI) of 18-32 kg/m2 * Male subject agrees to sexual abstinence, is surgically sterile or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method until 90 days after the last dose of study drug administration * Male subject agrees to not donate sperm until 90 days after the dose of study drug administration * Female subject is surgically sterile or is post-menopausal and is not pregnant and is not lactating * Subject's 12-lead electrocardiogram (ECG) is normal * Subject must be capable of swallowing multiple tablets
Exclusion criteria
* Subject has a previous history of any clinically significant gastro-intestinal, neurological, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, malignancy excluding non-melanoma skin cancer or any other medical condition * Subject has had major GI surgery (such as colectomy, cholecystectomy, etc) * Subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years * Subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week * Subject has a positive test for hepatitis C antibody, or positive test for hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody * Subject has a history of the human immunodeficiency virus (HIV) antibody * Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold test or T-SPOT® test * Subject received any vaccine within 60 days * Subject received an experimental agent within 30 days * Subject has an absolute neutrophil count (ANC) \< 2500 cells/mm3 * Subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days * Subject has a history of smoking or has used tobacco-containing products and nicotine or nicotine-containing products in the past six months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of pharmacokinetic parameters of ASP015K: Cmax, AUClast, and AUCinf | Up to Day 15 |
Secondary
| Measure | Time frame |
|---|---|
| Composite of pharmacokinetic parameters of ASP015K: tmax, apparent terminal elimination half-life (t1/2), apparent body clearance after oral dosing (CL/F), and apparent volume of distribution (Vz/F) | Up to Day 15 |
| Composite of pharmacokinetic parameters of ASP015K metabolite H2: Cmax, AUClast, AUCinf, tmax and t1/2 | Up to Day 15 |
Countries
United States
Outcome results
None listed